Crispr, the powerful gene-editing tool, is revolutionizing the speed and scope with which scientists can modify the DNA of organisms, including human cells. So many people want to use it—from academic researchers to agtech companies to biopharma firms—that new companies are popping up to staunch the demand. Companies like Synthego, which is using a combination of software engineering and hardware automation to become the Amazon of genome engineering. And Inscripta, which wants to be the Apple. And Twist Bioscience, which could be the Intel
Bill Fulkerson on 07 Jul 20For protein molecules that contribute to metabolism, interactions with other components of their metabolic pathway can be crucial. Scientists at the Max Planck Institute for Developmental Biology in Tübingen have now investigated a natural enzyme complex that comprises 10 enzymes with five distinct activities. They found that the molecular architecture is surprisingly compact, yet offers individual enzymes maximum free moving space, which opens up novel perspectives for drug discovery. The scientists have published their results in Nature Chemical Biology.
